Bavarian Nordic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Bavarian Nordic has a total shareholder equity of DKK10.4B and total debt of DKK16.1M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are DKK14.3B and DKK3.8B respectively. Bavarian Nordic's EBIT is DKK1.4B making its interest coverage ratio -18.2. It has cash and short-term investments of DKK2.2B.

Anahtar bilgiler

0.2%

Borç/özkaynak oranı

DKK 16.10m

Borç

Faiz karşılama oranı	-18.2x
Nakit	DKK 2.24b
Eşitlik	DKK 10.44b
Toplam yükümlülükler	DKK 3.84b
Toplam varlıklar	DKK 14.27b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0DPB's short term assets (DKK5.4B) exceed its short term liabilities (DKK3.6B).

Uzun Vadeli Yükümlülükler: 0DPB's short term assets (DKK5.4B) exceed its long term liabilities (DKK188.3M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0DPB has more cash than its total debt.

Borcun Azaltılması: 0DPB's debt to equity ratio has reduced from 20.3% to 0.2% over the past 5 years.

Borç Kapsamı: 0DPB's debt is well covered by operating cash flow (12157.7%).

Faiz Kapsamı: 0DPB earns more interest than it pays, so coverage of interest payments is not a concern.

Bavarian Nordic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Second quarter 2024 earnings released

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 16%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 21% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Now 41% undervalued

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations